Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Relay Therapeutics dropped for a second day on Tuesday, slashing 12.84 percent to finish at $13.03 apiece, as investors appeared to have taken profits after already jumping by 74 percent this month, thanks to positive data from its cancer treatment candidate, Zovegalisib. On Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) announced that it would officially kick off the third phase of its clinical study for zovegalisib in combination with atirmociclib—Pfizer's investigational, potential first-in-class CDK4 inhibitor—to test their efficacy in treating patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer. For illustration purposes only. Photo by RDNE on Pexels Zovegalisib is currently being evaluated in the ReDiscover trial, which aims to test the latter's combination with fulvestrant and CDK inhibitors. As of April 13, 69 total patients were enrolled, with 62 patients at or below the potential Phase 3 dose, and 34 patients with measurable disease evaluable for response
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026GlobeNewswire
- Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside [Seeking Alpha]Seeking Alpha
- Relay Therapeutics (RLAY) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- Relay Therapeutics (RLAY) had its price target raised by Citizens Jmp from $17.00 to $19.00. They now have a "market outperform" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- RLAY's page on the SEC website